

Does the Serum Testosterone Level has a Relation to Coronary Artery Disease in Elderly Men?

Mohamed A. Helaly¹, Eid Daoud², Noha El-Mashad³

ABSTRACT

The low serum level of testosterone in the elderly subjects may be a contributing factor for coronary artery disease (CAD) through many pathways. The aim of this work is to study serum levels of free testosterone in elderly men with CAD (both those with acute coronary syndrome (ACS) and those with stable CAD). This study was conducted on 100 elderly males with CAD, one half of them (50 patients) was presented with ACS (with mean age 69.6 ± 2.44 year), and the other half (50 patients) was presented with stable CAD (with mean age 69.42 ± 2.14 year), in addition to 50 apparently healthy elderly males (with mean age 69.06 ± 1.64 year) as a control group. We detected the levels of serum free testosterone, cortisol, fibrinogen, plasminogen activator inhibitor-1 (PAI-1), high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6). Cases with CAD had significant lower values of free testosterone and HDL-c, but they had significant higher values of cortisol, fibrinogen, PAI-1, IL-6, hsCRP, in comparison to control group. Cases with ACS had significant higher values of cortisol, hsCRP, IL-6, fibrinogen, PAI-1, total cholesterol and BMI more than those with stable CAD. The free testosterone had significant negative correlation with fibrinogen, PAI-1, hsCRP and IL-6 in both groups of patients. The lower value of serum free testosterone in elderly male subjects may contribute to CAD in them via multiple mechanisms including increase blood pressure, dyslipidemia, obesity, increased blood coagulation and increased inflammatory activity.

Key words: Testosterone, coronary artery disease, elderly, men.

Yaşlı Erkeklerde Koroner Arter Hastalığının Serum Testosteron Düzeyi ile İlişkisi Var Mı?

ÖZET

Yaşlı bireylerde düşük testosteron düzeyi, birçok mekanizma ile koroner arter hastalığı (KAH) gelişimine katkıda bulunabilir. Bu çalışmada KAH olan (akut koroner sendromu (AKS) veya stabil KAH olan) yaşlı erkeklerde serbest testosteron düzeylerinin incelenmesi amaçlanmıştır. Çalışmaya 50 AKS'li (ortalama yaş 69.6 ± 2.44), 50 stabil KAH (ortalama yaş 69.42 ± 2.14) olan toplam 100 hasta ve kontrol grubu olarak 50 sağlıklı yaşlı (ortalama yaş 69.06 ± 1.64) alındı. Çalışmaya alınan kişilerin serum serbest testosteron düzeyleri, kortizol, fibrinojen, plazminojen aktivatör inhibitör-1 (PAI-1), yüksek duyarlı C-reaktif protein (hsCRP), interleukin-6 (IL-6) düzeylerine bakıldı. Kontrol grubu ile karşılaştırıldığında, KAH olan olgularda serbest testosteron ve HDL-c düzeyleri anlamlı olarak düşük bulunurken, kortizol, fibrinojen, PAI-1, hsCRP, IL-6 düzeyleri yüksek bulundu. AKS'li hastalarda kortizol, fibrinojen, PAI-1, hsCRP, IL-6, total kolesterol ve BMI düzeyleri stabil KAH olan hastalardan önemli derecede yüksekti. Her iki grupta da serbest testosteron ile fibrinojen, PAI-1, hsCRP, IL-6 düzeyleri arasında negatif korelasyon vardı. Yaşlı erkek hastalarda serum serbest testosteron düzeyleri, tansiyon artışı, dislipidemi, aşırı şişmanlık, koagülasyon ve enflamatuar aktivite artışı gibi çoklu mekanizmalar yoluyla KAH'na katkıda bulunabilir.

Anahtar kelimeler: Testosteron, koroner arter hastalığı, yaşlı, erkek

From departments of Internal Medicine¹, Cardiology², and Clinical Pathology³; Faculty of Medicine, Mansoura University.

Correspondence: Mohamed A. Helaly, Internal Medicine department, Specialized Medical Hospital, B.O. Pox 35516, Al-Gomhoria Street, Mansoura, Egypt.
E-mail: helaly70@yahoo.com

Received: 05.03.2011, Accepted: 02.04.2013

INTRODUCTION

Coronary artery disease (CAD) is common in old people and accounts for about half of all deaths in those people (1). Phillips et al (1994) (2) reported that low total and free testosterone levels were inversely linked to coronary artery disease, even after adjusting for age and adiposity. This idea was supported by another study, in which men with angiographically proven CAD has lower levels of testosterone than those of control subjects, and the testosterone levels were negatively correlated to the degree of coronary involvement (3). Moreover, lower testosterone levels predict incident stroke and transient ischemic attacks in older men (4). Few studies were done for the association of testosterone level with CAD in elderly men.

The aim of this work is to study the levels of serum free testosterone in elderly patients with CAD (both those presenting with acute coronary syndrome and others with stable CAD), and the correlation of free testosterone with levels of serum cortisol, fibrinogen, PAI-1, hsCRP, and IL-6 in those patients.

MATERIAL AND METHODS

A total of 100 elderly male patients with CAD with mean age 65 years were taken from the cardiology and geriatric units (Age recruitment criteria, the man was >65), Specialized Medical Hospital, Mansoura University in the period between October 2009 to June 2010. The patients was then subsequently divided according to clinical presentation of CAD into group 1 which consists of 50 patients with acute coronary syndrome; (21 of them had ST elevation myocardial infarction (STEMI), 14 of them had non-ST elevation myocardial infarction (NSTEMI), and 15 had unstable angina, and group 2 which consists of 50 patients with stable CAD. This is in addition to 50 apparently healthy elderly subjects; they are non-smokers and had no risk factors for CAD as a control group (group 3). All cases and control subjects were subjected to thorough history taking with special stress on symptoms suggestive of CAD and/or symptoms of ACS and history of previous cardiac interventions done for the patient, in addition to full clinical examination, 12 lead ECG and echocardiography. Cases with stable CAD were diagnosed after coronary angiography. Unstable angina was diagnosed according to EKD only, if the patient had one or more of the following 3 principal presentations: (1) Rest angina (usually lasting 20 minutes), (2) New on-

set angina (2 months previously), (3) Crescendo angina (increasing in intensity, duration, frequency or any combination of these factors (5) with or without ECG changes in the form of ST-segment depression, transient ST-segment elevation, T-wave inversion, or some combination of these changes (6).

Patients with acute myocardial infarction were diagnosed if they had 2 of the following: (1) chest pain 30 minutes, (2) ≥ 2 fold increase in serum creatine phosphokinase (CK) with elevation of MB isoform $\geq 10\%$, (3) persistent ischemic ECG changes: evolution of pathologic Q-waves (≥ 0.04 second), or ≥ 1 mm ST segment elevation in at least 2 contiguous leads or new onset left bundle branch block (in cases of STEMI), or ≥ 0.5 mm ST-depression or definite T-wave inversion (in cases of NSTEMI) (7), and unfortunately Troponins not done. 10 ml of overnight fasting blood samples were drawn for determination of free testosterone, cortisol, fibrinogen, plasminogen activator inhibitor -1 (PAI-1), IL-6, hsCRP, total cholesterol, triglyceride (TG), low density lipoprotein-cholesterol (LDL-c), high density lipoprotein-cholesterol (HDL-c), creatinine, creatine phosphokinase (CPK) and MB-fraction. Free serum testosterone and serum cortisol were determined by radioimmunoassay (8, 9). PAI-1 level was detected by radioimmunoassay (10). Fibrinogen level was determined by clotting method (FIBRI- PREST2): 1:10 dilution of plasma was tested with buffer diluents (0.1 ml of plasma plus 0.9 ml of buffer), then dilutions in an ice bath were placed. Dilutions were stable for up to 4 hours. Clotting time was determined for each sample and duplicated. The average duplicated times for each dilution were obtained. The fibrinogen concentration was obtained from a calibration curve (11).

IL-6 was detected by goat anti-rabbit antibody immunoassay: goat anti-rabbit antibodies are used to capture a specific IL-6 complex in each sample consisting of IL-6 antibody, bio-tinylated IL-6, and sample/standard. The bio-tinylated IL-6 conjugate (competitive ligand) and sample or standard compete for IL-6 specific antibody binding sites. Therefore, as the concentration of IL-6 in the sample increases, the amount of bio-tinylated IL-6 captured by the antibody decreases. The assay is visualized using a streptavidin alkaline phosphatase conjugate and a chromogenic substrate reaction. The amount of IL-6 detected in each sample is compared to an IL-6 standard curve which demonstrates an inverse relationship between Optical Density (O.D.) and cytokine con-




Figure 1. Correlation of free testosterone with hsCRP in patients with ACS (group 1)




Figure 2. Correlation of free testosterone with hsCRP in patients with stable CAD (group 2)

centration: i.e. the higher the O.D. the lower the IL-6 concentration in the sample. hsCRP was detected using an enzymatically amplified 'two-step' sandwich type immunoassay, standards, controls and unknown samples were incubated in microtitration plates which have been coated with anti-hs-CRP antibody. After incubation and washing, wells were treated with another anti-hs-CRP detection antibody labelled with enzyme HRP. After a second incubation, wells were incubated with substrate FMB. An acidic stopping solution is then added and the degree of enzymatic turnover of the substrate is determined by measurement at 450nm. The absorbance

measured is directly proportional to the concentration of hs-CRP present. Results of these samples were multiplied by 500 to correct for the additional dilution.

Exclusion criteria

1- patients with major organ failure (heart, respiratory, liver or renal failure). 2- patients with cancer prostate, prostatectomy, castration or those receiving androgen deprivation therapy. 3- patients receiving androgens, steroids or hypolipidemic medications. 4- patients with diabetes mellitus or other endocrine disorders. 5- smoker patients and controls were also excluded from the

Table 1. Comparison of demographic, clinical and laboratory data of cases versus control group

	Cases (group 1 + group 2) Mean \pm S.D.	Control group (group 3) Mean \pm S.D.	p value
Age (years)	69.51 \pm 2.29	69.06 \pm 1.64	0.17
BMI (kg/m ²)	27.99 \pm 3.08	23.10 \pm 0.71	0.0001
SBP (mmHg)	146.70 \pm 9.02	125.20 \pm 7.28	0.0001
DBP (mm Hg)	91.76 \pm 9.36	75.20 \pm 7.14	0.0001
FPG (mg/dl)	87.95 \pm 12.71	79.08 \pm 5.49	0.0001
Serum creatinine (mg/dl)	1.09 \pm 0.19	1.02 \pm 0.09	0.004
Total cholesterol (mg/dl)	209.53 \pm 36.20	132.84 \pm 10.15	0.0001
TG(mg/dl)	161.61 \pm 53.27	80.24 \pm 7.09	0.0001
LDL-c(mg/dl)	142.82 \pm 35.84	76.88 \pm 7.49	0.0001
HDL-c(mg/dl)	37.96 \pm 4.97	47.66 \pm 5.06	0.0001
Cortisol (nmol/L)	359.10 \pm 137.47	220.14 \pm 45.01	0.0001
Free testosterone (pg/ml)	70.75 \pm 11.95	164.60 \pm 29.56	0.0001
hs CRP (mg/L)	14.81 \pm 9.74	1.45 \pm 0.60	0.0001
IL-6 (ng/ L)	7.33 \pm 3.22	1.94 \pm 0.59	0.0001
Fibrinogen (g/L)	5.66 \pm 1.19	2.93 \pm 0.64	0.0001
PAI-1 (ng/ ml)	56.05 \pm 13.56	24.24 \pm 9.37	0.0001

BMI= body mass index, DBP= diastolic blood pressure, FPG=fasting plasma glucose, HDL-c=high density lipoprotein-cholesterol, hsCRP= high sensitive C-reactive protein, IL-6= interleukin-6, LDL-c =low density lipoprotein-cholesterol, PAI-1= plasminogen activator inhibitor-1, Tg=triglycerides

Table 2. Comparison of group 1 (cases with ACS) versus group 2 (cases with stable CAD)

	Group 1 Mean \pm S.D.	Group 2 Mean \pm S.D.	p value
Age (years)	69.60 \pm 2.44	69.42 \pm 2.14	0.697
BMI (kg/m ²)	29.11 \pm 3.41	26.86 \pm 2.23	0.0001
SBP (mmHg)	148.60 \pm 9.53	144.80 \pm 8.14	0.035
DBP (mm Hg)	91.52 \pm 11.76	92.00 \pm 6.22	0.799
FPG (mg/dl)	85.98 \pm 14.33	89.92 \pm 10.65	0.122
Serum creatinine (mg/dl)	1.07 \pm 0.23	1.12 \pm 0.13	0.175
Total cholesterol (mg/dl)	224.22 \pm 33.25	194.84 \pm 33.20	0.0001
TG(mg/dl)	171.80 \pm 72.60	151.42 \pm 15.84	0.058
LDL-c(mg/dl)	151.98 \pm 39.97	133.66 \pm 28.74	0.010
HDL-c(mg/dl)	37.54 \pm 6.34	38.38 \pm 3.07	0.402
Cortisol (nmol/L)	487.36 \pm 25.52	230.84 \pm 62.91	0.0001
Free testosterone (pg/ml)	69.68 \pm 14.34	71.82 \pm 8.98	0.374
hs CRP (mg/L)	23.61 \pm 5.64	6.01 \pm 1.33	0.0001
IL-6 (ng/ L)	8.69 \pm 3.66	5.97 \pm 1.94	0.0001
Fibrinogen (g/L)	6.11 \pm 1.27	5.20 \pm 0.91	0.0001
PAI-1 (ng/ ml)	63.70 \pm 10.22	48.40 \pm 12.15	0.0001

study to avoid the possible interaction between smoking and testosterone serum level. 6-Those with active infection or auto-immune diseases were excluded.

Statistical analysis

The statistical analysis of the data was done using SPSS (Statistical Package of Social Science) Program version 10. The data was presented in the form of mean \pm standard deviation for quantitative data and frequency and proportion for qualitative data. For comparison statistical significance between 2 groups t-test was used. For qualitative data, Chi-square test was used. Pearson correlation coefficient was used to study correlation between variables. Significance was considered when the P-value less than 0.05 at a confidence interval 95%.

RESULTS

Cases with CAD (group 1 + 2) have significant higher values of BMI, systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting plasma glucose (FPG), serum creatinine, total cholesterol, triglyceride (TG), low density lipoprotein-cholesterol (LDL-c), serum cortisol, high sensitive C-reactive protein (hsCRP), interleukin-6 (IL-6), fibrinogen, plasminogen activator inhibitor-1 (PAI-1), but they have lower values of free testosterone and HDL-c in comparison to control group as shown in table (1). Cases with acute coronary syndrome (group-1) have significant higher values of BMI, total cholesterol, cortisol, hsCRP, IL-6, fibrinogen and PAI-1 more than

those with stable CAD (group 2), while there is no significant difference as regard free testosterone between both groups as shown in table (2). Free testosterone in cases with ACS, has significant negative correlation with BMI, SBP, DBP, FPG, serum creatinine, total cholesterol, TG, cortisol, hsCRP, IL-6, fibrinogen and PAI-1as shown in table (3) and in figure (1). The free testosterone also in cases with stable CAD, has significant negative correlation with BMI, serum creatinine, total cholesterol, LDL-c, hsCRP, IL-6, fibrinogen and PAI-1 as shown in table (3) and in figure (2).

DISCUSSION

Previous studies had suggested that hypogonadism and androgen deficiency were linked to CAD in men (2 , 12). Although our patients in this study had no hypogonadism, they had a significant lower serum free testosterone level in comparison to control subjects, but there is no significant difference regarding it between cases with ACS and those with stable CAD. This agree with Liu et al (2003) (13) who suggested that testosterone levels were consistently lower in men with CAD. The pathophysiology of cardiovascular risk of low testosterone serum level may be related to increased fat mass (14). A host of previous studies have suggested that reduced testosterone levels were associated with increased total cholesterol and LDL-c (15- 17), and increased TG and reduced HDL-c (18). In other studies, the systolic and diastolic blood pressures have been shown to be

Table 3. Correlation of free testosterone with other data in group 1 and group 2:

	Free testosterone in group 1		Free testosterone in group 2	
	Pearson correlation (V)	Significance (p value)	Pearson correlation (V)	Significance (p value)
Age	- 0.335	0.017	-0.361	0.010
BMI	-0.765	0.0001	-0.821	0.0001
SBP	-0.601	0.0001	-0.298	0.036
DBP	-0.457	0.001	0.038	0.796
FPG	-0.482	0.0001	-0.125	0.388
Serum creatinine	-0.543	0.0001	-0.559	0.0001
Total cholesterol	-0.546	0.0001	-0.431	0.002
TG	-0.419	0.002	-0.118	0.414
LDL-c	-0.091	0.531	-0.588	0.0001
HDL-c	0.164	0.256	0.114	0.430
Cortisol	-0.804	0.0001	-0.157	0.275
hs CRP	-0.982	0.0001	-0.871	0.0001
IL-6	-0.781	0.0001	-0.726	0.0001
Fibrinogen	-0.745	0.0001	-0.912	0.0001
PAI-1	-0.682	0.0001	-0.863	0.0001

inversely correlated with testosterone level (19). These studies agree with the results in our study in which the cases with CAD had significant higher values of BMI, SBP, DBP, FPG, total cholesterol, TG, LDL-c more than control subjects, but they had a significant lower values of HDL-c. Moreover, the cases with ACS had significant higher values of BMI, total cholesterol and LDL-c more than those with stable CAD. Dobrzycki et al (2003) (20) showed that patients with at least a 50% lesion of at least one coronary vessel had significantly elevated systolic and diastolic blood pressure, fibrinogen, and TG levels and reduction in ejection fraction, total and free testosterone and HDL-c. The morning serum cortisol level was significant higher in cases more than control subjects, and moreover its level was significant higher also in those with ACS more than those with stable CAD possibly related to stress induced by acute coronary event. In the Caperhilly Study (South Wales), Smith et al (2005) (21) followed more than 2500 men for a mean of 16.5 years and found that the cortisol/testosterone ratio had a specific association to ischemic heart disease, possibly related to chronic illness, mediated through insulin resistance.

The contribution of low testosterone level to development of CAD is not only through its deleterious effects on blood pressure, glucose tolerance and plasma lipid, but also because it increases blood coagulability via increasing fibrinogen, plasminogen activator inhibitor-1 and factor 7 (22). In our study, fibrinogen and PAI-1 serum levels were significant higher in cases with CAD

more than in control group, and moreover their values were significant higher in patients with ACS more than those with stable CAD. The levels of serum hsCRP and IL-6 in cases with CAD in our study were significant higher in comparison to control group. Their levels, moreover were also higher in cases with ACS more than in those with stable CAD which may indicate augmented inflammatory state in which low testosterone level may have a role. These results go with the previous studies like Yialamas et al (2007) (23) and Maggio et al (2006) (24) which found that androgen deficiency is associated with increased production of inflammatory cytokines. These associations were further validated by clinical trials showing improvement in lipid profile and reduction in inflammatory cytokines with testosterone treatment (25). The free testosterone serum level in patients with ACS in our study, had significant negative correlation with BMI, SBP, DBP, FPG, total cholesterol, TG, cortisol, fibrinogen, PAI-1, hsCRP and IL-6. Similarly, free testosterone serum level had significant negative correlation with BMI, total cholesterol, LDL-c, fibrinogen, PAI-1, hsCRP and IL-6 in cases with stable CAD. Dobs et al (2001) (26), investigated hypogonadal men who were treated for one year with testosterone patch to set up simple correlations. The authors found that BMI to have strong negative correlation with testosterone.

In conclusion, coronary artery disease (CAD) in elderly men is associated with low serum testosterone level even within normal range and this may contribute to its pathogenesis through increase in blood pressure and

glucose levels, dyslipidaemia, visceral obesity, endothelial dysfunction, increase in pro-inflammatory cytokines and this may explain the high incidence of CAD in elderly men. Whether testosterone supplementation for elderly men is beneficial in primary or secondary prevention of CAD in them?. This needs further prospective multicenter trial done on large number of population.

REFERENCES

- Glen SK and Boon NA. Coronary artery disease in the elderly. *Rev Clinical Gerontology* 1999;9:13-21.
- Phillips GB, Pinkernell BH, Jing TY: The association of hypotestosteronemia with coronary artery disease in men. *Arterioscler Thromb*1994;14: 701-6.
- Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. *Int J Imopot Res* 2007;19:176-82.
- Yeap Bu, Hyde Z, Almeida O, et al. Lower testosterone levels predict incident stroke and transient ischemic attacks in older men. *J Clin Endocrinol Metab* 2009;94(7): 2353-9.
- Braunwald E: Unstable angina. A classification. *Circulation* 1989; 80: 410- 4.
- Savonitto S, Ardissino D, and Granger CB. Prognostic value of the admission electrocardiogram in acute coronary syndromes. *JAMA* 1999; 281(8): 707-13.
- Paul SP, O' Gara P, Mahjoub ZA, et al. Geriatric patients with acute myocardial infarction: Cardiac risk factor profiles, presentation, thrombolysis, coronary interventions, and prognosis. *Am Heart J* 1996; 131(4): 710-5.
- Dyas J, Read GF, Riad-Fahmy. A simple robust assay for testosterone in male plasma using an I125-radio-ligand and a solid-phase separation technique. *Ann Clin Biochem* 1979;16:325-31.
- Riad-Fahmy D, Read GF, Gaskell SJ, Dyas J, Hindawi R. A simple, direct radioimmunoassay for plasma cortisol, featuring a I125 radioligand and a solid-phase separation technique. *Clin.Chem*1979; 25: 665-8.
- Kruihof EKO, Nicolosa G, and Bachmann F. Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. *Blood* 1987; 70: 1645-53.
- Alessi M, Ailloud M, and Juttov-Vague I: Features of risk thrombosis and atherosclerosis. *Feul Biol* 1994;179:39-41.
- Khaw K, Dowsett M, Folkerd E, et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) prospective population study. *Circulation* 2007;116:2694-701.
- Liu PY, Death AK, and Handelsman DJ: Androgens and cardiovascular disease. *Endocrin Rev* 2003;24:313-40.
- Laughlin GA, Barrett-Connor E, and Bergstrom J. Low serum testosterone and mortality in older men. *J Clin Endocr Metab* 2008;93:68-75.
- Haffner SM, Mykkanen L, Valdez RA, and Katz MS: Relationship of sex hormones to lipids and lipoproteins in non-diabetic men. *J Clin Endocr Metab* 1993;77:1610-5
- Simon D, Charles MA, Nahoul K, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study. *J Clin Endocrin Metab* 1997;82(2): 682-5.
- Barud W, Palusinski R, Beltkowski J, and Wojcicka G: Inverse relationship between total testosterone and anti-oxidized low density lipoprotein levels in aging males. *Atherosclerosis* 2002;164:282-8.
- Zmuda JM, Cauley JA, Kriska A, Glynn NW, Gutai JP, Kuller LH. Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men: a 13 year follow-up of former multiple risk factor intervention trial participants. *Am.J.Epidemiol* 1997;146: 609-17.
- Khaw KT and Barrett-Connor E. Blood pressure and endogenous testosterone in men: an inverse relationship. *J Hypertension* 1988;6:329-32.
- Dobrzycki S, Serwatka W, Nadlewski S, et al. An assessment of correlations between endogenous sex hormones levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. *J Med Invest* 2003;50:162-9.
- Smith G, Ben-Shlomo Y, Beswick A, Yarnell J, Lightman S, and Elwood P: Cortisol, testosterone, and coronary heart disease prospective evidence from the Caperhilly Study. *Circulation* 2005;112:332-40.
- Hake AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, and Pols HA: Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. *J Clin Endocrin Metab* 2002;87:3632-9.
- Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud, Hayes FJ. Acute steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotrophic hypogonadism. *J Clin Endocrin Metab* 2007;92:4254- 9.
- Maggio M, Basaria S, Ble A, Lauretani F, Bandinelli S, Ceda GP, Valenti G, Ling SM, Ferrucci L. Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. *J Clin Endocrin Metab* 2006;91:345-7.
- Malkin CJ, Pugh PJ, Jones RD, Kappor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. *J Clin Endocrin Metab* 2004;89: 3313-8.
- Dobs AS, Bachorik PS, Arver S, et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. *J Clin Endocrin Metab* 2001;86:1026-33.